Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
Supernus Pharmaceuticals (Nasdaq: SUPN) will announce its preliminary financial results for Q4 and full year 2021, along with its guidance for 2022, on February 28, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Supernus Pharmaceuticals (Nasdaq: SUPN) will announce its preliminary financial results for Q4 and full year 2021, along with its guidance for 2022, on February 28, 2022, after market close. A conference call hosted by CEO Jack Khattar and CFO Tim Dec will take place at 4:30 PM ET the same day. Investors can access the live webcast on the company's website. Supernus develops treatments for CNS diseases, with a portfolio covering epilepsy, migraine, and more.
Positive
- Anticipated announcement of preliminary Q4 and full year 2021 financial results.
- Full year 2022 financial guidance to be provided.
Negative
- None.
Details
News Market Reaction – SUPN
The recorded move for SUPN in the trading session of this news was -1.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report preliminary fourth quarter and full year 2021 financial results and full year 2022 financial guidance after the market closes on Monday, February 28, 2022.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the preliminary fourth quarter and full year 2021 financial results and full year 2022 financial guidance on Monday, February 28, 2022 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of financial results, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 |
| International dial-in: | (970) 315-0267 |
| Conference ID: | 9659395 |
| Conference Call Name: | Supernus Pharmaceuticals Preliminary Fourth Quarter and Full Year 2021 Financial Results Conference Call |
Following the live call, a replay will be available on the Company’s website, www.supernus.com, in the Investor Relations section. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in PD, cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.